Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Newly-diagnosed Aggressive B-cell NHL
NCT05164770Phase 3Unknown
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zanubrutinib in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Overall Response Rate at 3 years. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05164770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164770.